These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 31605289)

  • 1. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
    Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
    J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
    Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
    Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Surgery; 2020 Dec; 168(6):994-1002. PubMed ID: 32139141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
    Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
    PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
    Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
    World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
    Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
    Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
    Chikhladze S; Lederer AK; Kousoulas L; Reinmuth M; Sick O; Fichtner-Feigl S; Wittel UA
    World J Surg Oncol; 2019 Nov; 17(1):185. PubMed ID: 31706323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of a Multidisciplinary Pancreatic Cancer Conference in Predicting and Managing Resectable Pancreatic Cancer.
    Rao B; Syed A; Singh S; Gulati A; Moussiade G; Garg M; Sharma M; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Tang A; Dhawan M; Kulkarni A; Thakkar S
    Pancreas; 2019 Jan; 48(1):80-84. PubMed ID: 30451791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
    Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
    World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer.
    Gruhl JD; Garrido-Laguna I; Francis SR; Affolter K; Tao R; Lloyd S
    Cancer Med; 2020 Mar; 9(5):1703-1711. PubMed ID: 31945808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Surgical therapy of pancreatic cancer - 5 years survival].
    Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
    Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.
    Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z
    Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.